Familial progressive hyperpigmentation

Familial progressive hyperpigmentation
Autosomal dominant - en.svg
This condition is inherited in an autosomal dominant manner
Synonyms	Melanosis universalis hereditaria
Specialty	Dermatology, Genetics
Symptoms	Progressive patches of hyperpigmentation
Complications	Cosmetic concerns, psychosocial impact
Usual onset	Congenital (present at birth)
Duration	Lifelong
Causes	Genetic disorder
Risk factors	Family history
Diagnosis	Clinical diagnosis, Genetic testing
Differential diagnosis	Lentiginosis, Neurofibromatosis, McCune-Albright syndrome
Prevention	None
Treatment	Topical corticosteroids, Laser therapy, Hydroquinone
Medication	Skin-lightening agents
Prognosis	Benign, but progressive
Frequency	Rare
Deaths	None

Familial progressive hyperpigmentation (FPH) is a rare genetic disorder characterized by progressive patches of hyperpigmentation, present at birth, which increase in size and number over time. The underlying genetic mutation responsible for this condition has not been fully identified, but the disorder is known to follow an autosomal dominant inheritance pattern. It is most commonly observed in populations originating from China.

Clinical Presentation

Individuals with familial progressive hyperpigmentation exhibit:

• Congenital onset – Hyperpigmented macules and patches are present from birth
• Progressive darkening – Lesions enlarge and increase in number with age
• No associated systemic abnormalities – Unlike some other genetic pigmentation disorders, FPH does not involve other organs

Genetic Basis

Although the exact genetic mutation remains unidentified, familial progressive hyperpigmentation is inherited in an autosomal dominant pattern, meaning an affected individual has a 50% chance of passing the condition to offspring. Genetic linkage studies suggest possible involvement of genes regulating melanocyte function, but no specific loci have been confirmed.

Differential Diagnosis

FPH must be distinguished from other pigmentation disorders:

• Lentiginosis – Clustered brown macules that may be associated with systemic abnormalities
• Neurofibromatosis type 1 – Café-au-lait macules with neurofibromas
• McCune-Albright syndrome – Irregular café-au-lait macules with endocrine dysfunction

Diagnosis

Diagnosis is based on:

• Clinical examination – Distribution and progression of pigmentation
• Family history – Inheritance pattern suggests a genetic component
• Genetic testing – Although no specific gene is identified, genetic sequencing may be considered in future research

Treatment

There is no cure for familial progressive hyperpigmentation, but treatment options may include:

• Topical corticosteroids – May reduce hyperpigmentation temporarily
• Hydroquinone or Skin-lightening agents – Depigmenting agents to lighten affected areas
• Laser therapy – Experimental approach for targeted removal of hyperpigmented areas

Prognosis

• Benign condition – No known systemic involvement
• Progressive but non-life-threatening – The disorder does not affect lifespan but may cause cosmetic and psychological distress
• Future genetic research – Identification of causative genes may lead to targeted therapies

Recent Research

New studies focus on genomic sequencing and potential molecular targets:

• A 2009 study in The American Journal of Human Genetics suggested possible involvement of melanocyte differentiation genes, although no single mutation has been confirmed.
• Advances in CRISPR gene-editing and melanin synthesis regulation may provide future treatment options.

See Also

• Skin lesion
• Hyperpigmentation
• Dermatology